Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients with Cirrhosis: a Randomized, Controlled Trial – Gastroenterology

Over a 6-month period, daily intake of VSL#3® significantly reduced the risk of hospitalization for HE, as well as Child-Turcotte-Pugh and model for end-stage liver disease scores, in patients with cirrhosis. ClinicalTrials.gov number: NCT01110447

via Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients with Cirrhosis: a Randomized, Controlled Trial – Gastroenterology.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s